1. Clinical practice guidelines in oncology-ovarian cancer, version 1. 2005. National Comprehensive cancer Network; 2005.
2. ESMO Guidelines Task Force: minimum clinical recommendations for diagnosis, triatment and follow-up of ovarian cancer. Switzerland: ESMO; 2002. Available at: http://www.esmo.org/reference/referenceGuidelines/html/MCR6.htm [accessed November 28, 2005].
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519–29.
4. The ICON and AGO Collaborators. Paclitaxel plus platimun-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099–106.
5. Pujade-Lauraine E, Paraiso D, Cure H et al. Predicting the effectiveness of chemotherapy (CX) in patients with recurrent ovarian cancer (ROC): a GINECO study (abstract 829). Proc Am Soc Clin Oncol 2002; 21: 208a.
6. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemothrapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 1989.
7. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer: technology appraisal 91. London: National Institute for Health and Clinical Exellence; 2005.
8. Markman M, Markman J, Webster K et al. Duration of response  to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22: 3120–5.
9. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005; 15 (Suppl. 1): 3–11.
10. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patient. Ann Oncol 1997; 8: 963–8.
11. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previosly treated with cisplatin. J Clin Oncol 1991; 9: 389–93.
12. Gore ME, Fryatt I, Wiltshaw E, Dawson t. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these components. Gynecologic Oncol 1990; 36: 207–11.
13. O'Byrne KJ, Bliss P, graham JD et al. A phase III study of Doxi/Caelyx versus paclitaxel in platinum-treated, taxane-maive relapsed ovarian cancer (abstract 8008). Proc Am Soc Clin Oncol 2002; 21: 203a.
14. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versjus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–93.
15. International topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100–3.
16. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Core ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312–22.
17. Doxil stury 30–49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2044; 95: 1–8.
18. Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated afterprior chemotherapy that contained cisplatin and paclitaxel. J clin Oncol 1998; 16 (10): 3345–52.
19. AGO-OVAR NCIC CTG & EORTC GCG. Combination therapy with gemciabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15 (Suppl. 1): 36–41.
20. Cannistra SA. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 2002; 20: 1158–60.
21. Meier W, duBois A, Reuss A et al. topotecan versus treosulfan in early recurrent ovarian cancer after primary platinum/paclitaxel chemotherapy. A prospective randomized phase III trial of the AGO ovarian cancer study group (abstract 005). Int J Gynecol Cancer 2004; 14 (Suppl. 1): 2.
22. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reintroduction after taxane in patients with platinum-refractgory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584–8.
23. See HT, Freedman RS, Kudelka AP et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005; 15: 209–16.
24. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of Bcl-x1, can confer a multidrug resistance phenotype. Blood 1995; 86: 1903–10.
Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772–7.
26. Smith DH, Adams JR, Johnstone SRD. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 2002; 13: 1590–7.
27. Capri S, Cattaneo G. Cost-minimization analisis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in taly. Clin Ther 2003; 25: 1826–35.
28. Ojeda B, De Sande LM, Casado A et al. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer 2003; 89: 1002–7.
29. Bennett CL, Calhoum EA. Pharmacoeconomics of liposomal anthracycline therapy. Semin Oncol 2004; 31 (suppl. 13): 191–5.
30. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004; 10: 7439–49.
31. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005; 10: 205 14.
32. Ferrero JM, Weber B, Geay J-F et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007; 18: 263–8.
33. Hilpert F, Loibl S, Huober J et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in malignant gynecologictumors. A prospective multicenter phase II trial of the AGO-OVAR and the AGO Kommission Uterus (AGO-K-Ut). 2006 ASCO Meeting Proceedings Part I. J Clin Oncol 2006; 24: 5095.
34. Salzberg M, Thurlimann B, Bonnefois H et al. Current concepts of treatment streategiaes in advanced or recurrent ovarian cancer. Oncology 2005; 68: 293–8.

________________________________________________

N. Colomboa, M. Goreb

a European Institute of Oncology, University of Milan, Bicocca, Milan, Italy;
b Royal Marsden Hospital and Institute of Cancer search, london, UK